

# **Panuveitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034**

<https://marketpublishers.com/r/PFA2FC7C6127EN.html>

Date: May 2024

Pages: 130

Price: US\$ 6,499.00 (Single User License)

ID: PFA2FC7C6127EN

## **Abstracts**

The 7 major panuveitis markets are expected to exhibit a CAGR of 7.45% during 2024-2034.

The panuveitis market has been comprehensively analyzed in IMARC's new report titled "Panuveitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Panuveitis is a rare and potentially serious inflammatory eye condition that affects the uvea, the middle layer of the eye comprising the ciliary body, iris, and choroid. The symptoms of the ailment can vary in intensity and may include eye pain, redness, sensitivity to light (photophobia), blurred vision, floaters, and even vision loss. This illness can be caused by numerous factors, such as infections, autoimmune disorders, or underlying systemic diseases. The diagnosis of panuveitis typically involves a comprehensive eye examination by an ophthalmologist. The doctor may assess the patient's medical history, clinical symptoms, and perform various tests, including a visual acuity assessment, a slit-lamp examination to view the anterior eye structures, and indirect ophthalmoscopy to examine the posterior segment. Diagnostic imaging, such as optical coherence tomography (OCT) and fluorescein angiography, may also be conducted to visualize the retina and choroid, aiding in confirming the diagnosis and determining the severity of inflammation.

The increasing cases of autoimmune and inflammatory diseases, such as rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus, etc., in which the immune system attacks the eye tissues, are primarily driving the panuveitis market. In addition to this, the inflating utilization of advanced therapeutic approaches, such as immunosuppressive medications and disease-modifying antirheumatic drugs (DMARDs), is also creating a positive outlook for the market. These efficacious

treatments aim to mitigate inflammation, alleviate symptoms, and prevent irreversible damage to the uveal tract and surrounding ocular structures. Moreover, the widespread adoption of surgical interventions like vitrectomy and the implantation of sustained-release devices that are designed to address severe cases of panuveitis, thereby offering patients improved outcomes and enhanced quality of life, is further bolstering the market growth. Apart from this, the rising usage of physical therapies, aimed at strengthening visual and muscular coordination around the eye region is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, since it works by introducing functional genes to rectify or substitute the faulty ones implicated in disease manifestation, is also augmenting the market growth. Furthermore, the escalating application of targeted therapies, which offer tailored treatment options based on individual patient needs, is expected to drive the panuveitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the panuveitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for panuveitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the panuveitis market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the panuveitis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the panuveitis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current panuveitis marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the panuveitis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the panuveitis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the panuveitis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of panuveitis across the seven major markets?

What is the number of prevalent cases (2018-2034) of panuveitis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of panuveitis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with panuveitis across the seven major markets?

What is the size of the panuveitis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of panuveitis?

What will be the growth rate of patients across the seven major markets?

### Panuveitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for panuveitis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the panuveitis market?

What are the key regulatory events related to the panuveitis market?

What is the structure of clinical trial landscape by status related to the panuveitis market?

What is the structure of clinical trial landscape by phase related to the panuveitis market?

What is the structure of clinical trial landscape by route of administration related to the panuveitis market?

## Contents

?1 Preface

### **2 SCOPE AND METHODOLOGY**

2.1 Objectives of the Study

2.2 Stakeholders

2.3 Data Sources

2.3.1 Primary Sources

2.3.2 Secondary Sources

2.4 Market Estimation

2.4.1 Bottom-Up Approach

2.4.2 Top-Down Approach

2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 PANUVEITIS - INTRODUCTION**

4.1 Overview

4.2 Regulatory Process

4.3 Epidemiology (2018-2023) and Forecast (2024-2034)

4.4 Market Overview (2018-2023) and Forecast (2024-2034)

4.5 Competitive Intelligence

### **5 PANUVEITIS - DISEASE OVERVIEW**

5.1 Introduction

5.2 Symptoms and Diagnosis

5.3 Pathophysiology

5.4 Causes and Risk Factors

5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 PANUVEITIS - EPIDEMIOLOGY AND PATIENT POPULATION**

7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 PANUVEITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 PANUVEITIS - UNMET NEEDS**

## **10 PANUVEITIS - KEY ENDPOINTS OF TREATMENT**

## **11 PANUVEITIS - MARKETED PRODUCTS**

- 11.1 List of Panuveitis Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Humira (Adalimumab) - AbbVie/AstraZeneca
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.



## **12 PANUVEITIS - PIPELINE DRUGS**

### 12.1 List of Panuveitis Pipeline Drugs Across the Top 7 Markets

- 12.1.1 ESK001 - Alumis
  - 12.1.1.1 Drug Overview
  - 12.1.1.2 Mechanism of Action
  - 12.1.1.3 Clinical Trial Results
  - 12.1.1.4 Safety and Efficacy
  - 12.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13 PANUVEITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14 PANUVEITIS – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 PANUVEITIS - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Panuveitis - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)
  - 15.2.2 Panuveitis - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2018-2023)
    - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Panuveitis - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Panuveitis - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)

- 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Panuveitis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Panuveitis - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Panuveitis - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Panuveitis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Panuveitis - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Panuveitis - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Panuveitis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Panuveitis - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Panuveitis - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Panuveitis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Panuveitis - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Panuveitis - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Panuveitis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Panuveitis - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Panuveitis - Market Size by Therapies

- 15.8.2.1 Market Size by Therapies (2018-2023)
- 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Panuveitis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Panuveitis - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Panuveitis - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Panuveitis - Access and Reimbursement Overview

## **16 PANUVEITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 PANUVEITIS MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 PANUVEITIS MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Panuveitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/PFA2FC7C6127EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PFA2FC7C6127EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

